We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Bacteria Engineered to Detect Tumor DNA Could Seek and Destroy Gastrointestinal and Other Cancers

By LabMedica International staff writers
Posted on 11 Aug 2023

Tumors release their DNA into their surrounding environment, a phenomenon known as shedding. More...

While various technologies can analyze purified DNA in laboratory settings, they fall short in detecting DNA in its released state. Although bacteria have been engineered for diverse diagnostic and therapeutic tasks, they cannot recognize specific DNA sequences and mutations outside of cells. Now, researchers have engineered bacteria that can identify tumor DNA in a live organism. This innovation, which successfully detected cancer in the colons of mice, has the potential for the creation of new biosensors to identify infections, cancers, and other diseases.

Under the new “Cellular Assay for Targeted CRISPR-discriminated Horizontal gene transfer,” or “CATCH,” strategy, scientists from the University of California San Diego (La Jolla, CA, USA) used CRISPR technology to engineer bacteria capable of assessing free-floating DNA sequences on a genomic level. These samples were then compared with predetermined cancerous sequences. The concept involved repurposing bacteria that are naturally present in the colon as biosensors, capable of detecting DNA released from colorectal tumors. The focus was on Acinetobacter baylyi, a bacterium in which the essential components for both acquiring DNA and utilizing CRISPR for analysis were identified.

The researchers proceeded to design, construct, and assess Acinetobacter baylyi as a sensor for detecting DNA from the KRAS gene, which is frequently mutated in various cancers. They programmed the bacterium with a CRISPR system to differentiate between mutant and normal (non-mutated) variants of the KRAS gene. Consequently, only bacteria that had incorporated mutant KRAS forms, as present in precancerous growths and cancers, would survive to indicate or respond to the disease. This research builds upon the concept of horizontal gene transfer, a method by which genetic material is exchanged among organisms in a manner distinct from traditional genetic inheritance. While horizontal gene transfer is commonly observed between bacteria, the researchers successfully adapted this concept from mammalian tumors and human cells into bacteria.

The researchers are presently refining their bacteria-based biosensor strategy, exploring new circuits and various bacterial species for detecting and treating human cancers and infections. Researchers believe that in the future, cellular interventions will surpass traditional medicinal approaches. A living bacterium capable of detecting DNA within the gastrointestinal tract holds remarkable potential as a sentinel for identifying and combating gastrointestinal cancers, along with numerous other malignancies.

“There is so much potential to engineer bacteria to prevent colorectal cancer, a tumor that is immersed in a stream of bacteria, that could help, or hinder, its progression,” said researcher Susan Woods.

Related Links:
UC San Diego


Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gel Cards
DG Gel Cards
Human Estradiol Assay
Human Estradiol CLIA Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.